1. l-Tetrahydropalmatine can ameliorate behavioral phenotype induced by METH through regulation of 5-HT neuronal activity and dopamine D3 receptor expression.
2. Tetrahydropalmatine has a promyogenic effect by upregulation of p38MAPK and Akt resulting in enhanced MyoD activation, suggests that it has a potential as a therapeutic candidate to prevent fibrosis and improve muscle regeneration and repair.
3. DL-tetrahydropalmatine acts through the 5-HT2 and/or D2-receptor antagonism in the hypothalamus to induce hypotension and bradycardia in rats.
4. DL-tetrahydropalmatine (dl-THP) has been intensively studied for its sedative and hypnotic effects,dl-THP at defined low dosages acts as anxiolytics in mice, and the benzodiazepine site (BDS) mediates, at least in part, such anxiolytic effect of dl-THP.
5. Tetrahydropalmatine can effectively protect endothelial cells against γ-irradiation injury, which can potentially be applied to the prevention of endothelial cell dysfunctions associated with ionizing irradiation-induced lung injury.
6. Levo-tetrahydropalmatine inhibits cocaine's rewarding effects.
1. Ibogaine has the propensity to prolong the QT interval of the electrocardiogram in humans, may generate life-threatening cardiac arrhythmias .
2. Ibogaine has promising anti-addictive property in animals.
1. L-Stepholidine, which has dual actions on dopamine D1 and D2 receptors, attenuates heroin self-administration and cue-induced reinstatement.
2. L-Stepholidine elicits anti-dyskinesia effects via both dopamine (D(2) receptor antagonistic activity) and nondopamine (5-HT(1A) agonistic activity) mechanisms.
1. l-isocorypalmine (l-ICP), l-ICP likely acts as a D1 partial agonist and a D2 antagonist to produce its in vivo effects and may be a promising agent for treatment of cocaine addiction.
2. (-)-Isocorypalmine has significant antifungal activity.